Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1555
Title: | Long-term survival after surgery and radiotherapy for recurrent or persistent ovarian and tubal cancer |
Epworth Authors: | Rome, Robert Leung, Samuel |
Other Authors: | Dipnall, Joanna |
Keywords: | Disease-Specific Survival DSS Radiotherapy RT Recurrent Ovarian Cancer Recurrent Tubal Cancer Ovarian/Endometrial Carcinoma Persistent Cancer Second-Look Surgery Long-Term Survival Univariate Analysis Initial Stage I Initial Stage II Initial Stage III Initial Stage IV Endometrioid History Macroscopic Tumor Localized Tumor Widespread Tumor Limited-Volume Radiotherapy Field Multivariate Analysis Chemotherapy Bowel Complications Adhesions Malignancy Debulk Irradiated Increased Risk Disease Management Obstetrics and Gynaecology Clinical Institute, Epworth HealthCare, Victoria, Australia Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia Epworth Radiation Oncology, Epworth HealthCare, Victoria, Australia |
Issue Date: | Jul-2018 |
Publisher: | LWW |
Citation: | Int J Gynecol Cancer. 2018 Jul;28(6):1090-1100. |
Abstract: | OBJECTIVE: This study examines the factors associated with long-term disease-specific survival (DSS) and complications after radiotherapy (RT) for recurrent or persistent ovarian and tubal cancer. METHODS/MATERIALS: Between 1980 and 2015, 65 women with ovarian (57), tubal (3), or co-existent ovarian/endometrial carcinoma (5) received RT (>45 Gy) with curative intent for recurrent (45) or persistent cancer (20) found at second-look surgery. Surgery to debulk (± restage) was integrated into the management of all but 7 cases. RESULTS: Twenty-two women had no evidence of disease at last contact after a median of 15.6 years (range = 1.0-35.8 years). Of the 53 patients treated more than 10 years ago, 18 (34%) are in this long-term no evidence of disease group. Univariate analysis showed that the following factors were significantly associated with longer DSS (P < 0.05): initial stage I, II (vs III, IV); endometrioid histology (vs serous and other); no or 1 previous chemotherapy (vs ≥2); no macroscopic tumor before RT (vs macroscopic); localized tumor encompassed by a limited-volume RT field (vs more widespread tumor), and chemotherapy and RT (vs RT only). Multivariate analysis showed that endometrioid (vs other histology HR = 4.37, P = 0.017) and localized tumor (vs more widespread tumor, HR = 2.43, P = 0.017) were significantly associated with longer DSS.After RT to the pelvis and/or abdomen, 13 (21.7%) of 60 patients developed G3 or 4 bowel complications requiring surgery. In 10, these occurred in the presence of tumor, RT changes, and adhesions, and in 3, there was no sign of cancer. Six patients (9.2%) developed a subsequent malignancy. CONCLUSIONS: We conclude that there is a role for the use of RT in selected cases of localized recurrent or persistent ovarian cancer and may confer long-term survival. Surgery is useful to debulk and define the extent of tumor to be irradiated but may confer an increased risk of severe bowel complications. |
URI: | http://hdl.handle.net/11434/1555 |
DOI: | 10.1097/IGC.0000000000001294 |
PubMed URL: | https://www.ncbi.nlm.nih.gov/pubmed/29846300 |
ISSN: | 1048-891X 1525-1438 |
Journal Title: | International Journal of Gynecological Cancer |
Type: | Journal Article |
Affiliated Organisations: | School of Medicine, Deakin University, Geelong Radiation Oncology Victoria, Frankston, VIC, Australia Epworth HealthCare, Richmond VIC, Australia |
Type of Clinical Study or Trial: | Case Series and Case Reports |
Appears in Collections: | Cancer Services Radiation Oncology Women's and Children's |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.